Anger. Frustration. Finger-pointing. Emotions are running high in the CME community in reaction to the U.S. Senate Finance Committee report on CME. Issued in April, the report expressed strong concerns that the Accreditation Council for CME's oversight is not enough to guarantee that educational programs are independent of pharmaceutical industry influence. The ACCME will formulate a plan to respond during its July board meeting, says Murray Kopelow, MD, chief executive; the committee will ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Printer-friendly, you'll get exclusive access to a large archive of premium content.

Already registered? here.